A Phase 2 interventional study of Roflumilast and Roflumilast placebo in Asthma, sponsored by AstraZeneca. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-01.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing roflumilast in Asthma — none open to participants now, none under way, none of them phase 3. Roflumilast · Asthma.
Among the 10 studies testing roflumilast in Asthma, this one is the 7th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 2, and was the 8th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →None of the 10 studies testing roflumilast in Asthma is open now. The open studies under Asthma, anywhere →
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2003; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 300 across the 10 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 3 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 169th largest by enrollment of the 248 interventional ones that give a count, is one of 7 that started in 2013, is one of 50 in phase 2, and was the 173rd registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing roflumilast in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).
The drug being tested in this study is called roflumilast. Roflumilast is being tested to treat people who have asthma. This study will look at lung function and asthma symptoms of people who take roflumilast in combination with montelukast.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks.
Drug: Roflumilast · Drug: Roflumilast placebo · Drug: Montelukast
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks.
Drug: Roflumilast · Drug: Roflumilast placebo · Drug: Montelukast
Roflumilast was supplied in tablets.
Also known as: Daxas, Daliresp
Roflumilast placebo was supplied in tablets.
Montelukast was supplied in tablets.
Also known as: Singulair, Pluralair
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 will be measured using spirometry in accordance with the American Thoracic Society / European Respiratory Society (ATS/ERS) consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEV1 measurement as the covariate was used for analysis.
Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Vital Capacity (FVC)
FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FVC measurement as the covariate was used for analysis.
Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Flow (FEF) 25-75%
FEF is a measure of how much air can be exhaled from the lungs. It is an indicator of obstruction of the smaller airways. FEF25-75% is the mid-flow rate or forced expiratory flow occurring in the middle 50% of the patient's exhaled volume, and will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEF measurement as the covariate was used for analysis.
Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Peak Expiratory Flow (PEF)
PEF is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways. PEF will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.
Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Change From Baseline in Morning Peak Expiratory Flow (PEF)
PEF will be measured at home using portable electronic peak flow meter. The participant will record PEF daily in the morning immediately after getting up. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.
Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Change From Baseline in Daytime Asthma Symptoms
Patients will assess their daily day-time asthma symptoms according to the following scale: 0: Very well, no symptoms. 1: One episode of wheezing, cough or breathlessness. 2: More than one episode of wheezing, cough or breathlessness without interfering with normal activities. 3: Wheezing, cough or short of breath most of the day which interfered to some extent with normal activities. 4: Asthma very bad. Unable to carry out daily activities as usual. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Daytime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.
Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Change From Baseline in Nighttime Asthma Symptoms
Patients will assess their daily night-time asthma symptoms according to the following scale: 0: No symptoms, slept through the night. 1: Slept well but some complaints in the morning. 2: Woke up once because of asthma (inclusive early awakening). 3: Woke up several times because of asthma (inclusive early awakening). 4: Bad night, awake most of the night because of asthma. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Nighttime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.
Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Participants took part in the study at 12 investigative sites in Germany, Hungary, and South Africa from 15 February 2013 to 24 October 2013.
| Milestone | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast |
|---|---|---|
| Started | 32 | 32 |
| Completed | 32 | 31 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast |
|---|---|---|
| Started | 32 | 31 |
| Completed | 30 | 30 |
| Not completed | 2 | 1 |
| Withdrew: Voluntary withdrawal | 1 | 1 |
| Withdrew: Reason not specified | 1 | 0 |
| Milestone | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 28 |
| Not completed | 0 | 2 |
| Withdrew: Reason not specified | 0 | 2 |
| Milestone | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast |
|---|---|---|
| Started | 30 | 28 |
| Completed | 30 | 27 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 will be measured using spirometry in accordance with the American Thoracic Society / European Respiratory Society (ATS/ERS) consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEV1 measurement as the covariate was used for analysis.
| liters | Roflumilast Plus Montelukast | Placebo Plus Montelukast |
|---|---|---|
| Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | 0.18 ± 0.028 | 0.08 ± 0.027 |
FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FVC measurement as the covariate was used for analysis.
| liters | Roflumilast Plus Montelukast | Placebo Plus Montelukast |
|---|---|---|
| Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Vital Capacity (FVC) | 0.12 ± 0.029 | 0.06 ± 0.027 |
FEF is a measure of how much air can be exhaled from the lungs. It is an indicator of obstruction of the smaller airways. FEF25-75% is the mid-flow rate or forced expiratory flow occurring in the middle 50% of the patient's exhaled volume, and will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEF measurement as the covariate was used for analysis.
| liters/second | Roflumilast Plus Montelukast | Placebo Plus Montelukast |
|---|---|---|
| Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Flow (FEF) 25-75% | 0.23 ± 0.039 | 0.11 ± 0.039 |
PEF is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways. PEF will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.
| liters/minute (L/min) | Roflumilast Plus Montelukast | Placebo Plus Montelukast |
|---|---|---|
| Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Peak Expiratory Flow (PEF) | 15.05 ± 10.616 | 7.85 ± 10.401 |
PEF will be measured at home using portable electronic peak flow meter. The participant will record PEF daily in the morning immediately after getting up. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.
| L/min | Roflumilast Plus Montelukast | Placebo Plus Montelukast |
|---|---|---|
| Change From Baseline in Morning Peak Expiratory Flow (PEF) | 20.85 ± 3.708 | 7.23 ± 3.646 |
Patients will assess their daily day-time asthma symptoms according to the following scale: 0: Very well, no symptoms. 1: One episode of wheezing, cough or breathlessness. 2: More than one episode of wheezing, cough or breathlessness without interfering with normal activities. 3: Wheezing, cough or short of breath most of the day which interfered to some extent with normal activities. 4: Asthma very bad. Unable to carry out daily activities as usual. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Daytime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.
| units on a scale | Roflumilast Plus Montelukast | Placebo Plus Montelukast |
|---|---|---|
| Change From Baseline in Daytime Asthma Symptoms | -0.39 ± 0.061 | -0.18 ± 0.063 |
Patients will assess their daily night-time asthma symptoms according to the following scale: 0: No symptoms, slept through the night. 1: Slept well but some complaints in the morning. 2: Woke up once because of asthma (inclusive early awakening). 3: Woke up several times because of asthma (inclusive early awakening). 4: Bad night, awake most of the night because of asthma. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Nighttime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.
| units on a scale | Roflumilast Plus Montelukast | Placebo Plus Montelukast |
|---|---|---|
| Change From Baseline in Nighttime Asthma Symptoms | -0.27 ± 0.053 | -0.17 ± 0.052 |
Collected over Baseline to the end of the study (Days 1-105). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast Plus Montelukast | — | 0/61 (0%) | 5/61 (8.2%) |
| Placebo Plus Montelukast | — | 0/62 (0%) | 0/62 (0%) |
| Event | Roflumilast Plus Montelukast | Placebo Plus Montelukast |
|---|---|---|
| HeadacheNervous system disorders | 5/61 | 0/62 |
Full analysis set: All randomized participants, analyzed according to the randomized treatment.
| Age, Continuous(years) | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | Total |
|---|---|---|---|
| Mean | 50.3 ± 13.80 | 50.0 ± 14.10 | 50.1 ± 13.84 |
| Age, Customized(participants) | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | Total |
|---|---|---|---|
| < 65 years | 27 | 27 | 54 |
| ≥ 65 years | 5 | 5 | 10 |
| Gender(Participants) | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | Total |
|---|---|---|---|
| Female | 21 | 20 | 41 |
| Male | 11 | 12 | 23 |
| Race/Ethnicity, Customized(participants) | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | Total |
|---|---|---|---|
| Black or African American | 3 | 0 | 3 |
| White | 29 | 32 | 61 |
| Region of Enrollment(participants) | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | Total |
|---|---|---|---|
| South Africa | 16 | 11 | 27 |
| Germany | 8 | 12 | 20 |
| Hungary | 8 | 9 | 17 |
| Height(cm) | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | Total |
|---|---|---|---|
| Mean | 163.7 ± 8.47 | 168.3 ± 10.68 | 166.0 ± 9.85 |
| Weight(kg) | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | Total |
|---|---|---|---|
| Mean | 79.06 ± 18.708 | 85.16 ± 17.491 | 82.11 ± 18.227 |
| Body Mass Index (BMI)(kg/m^2) | Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | Total |
|---|---|---|---|
| Mean | 29.53 ± 7.105 | 30.06 ± 5.605 | 29.79 ± 6.354 |
1 further baseline measures are reported on the registry.
The record gives a start of Feb 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Roflumilast · Montelukast